CVS Health Corporation Stock Price Targets

Comprehensive analysis of short, mid, and long-term price targets for CVS Health Corporation (CVS).

Back to Analysis Hub

Give me a comprehensive price target analysis for CVS Health Corporation (CVS).

Below is a comprehensive CVS Health Corporation (CVS) analysis with three horizontal price targets plotted on the chart (Low, Median, High) and a detailed narrative using the data you provided.

Note on the price targets and chart lines

  • Target levels chosen (based on forward earnings framework and scenario analysis):
    • Low Target: 72.00
    • Median Target: 85.00
    • High Target: 98.00
  • Horizontal lines drawn to extend 30 days into the future from today (today = 2025-10-10). The lines extend to 2025-11-09.
  • Colors used for the lines:
    • Low Target (72): Dodger Blue (#1E90FF)
    • Median Target (85): Orange (#FFA500)
    • High Target (98): Red (#FF0000)

You can see these lines drawn on CVS’s price chart in the system (summary: lines created successfully at 72, 85, and 98).

Executive Summary

  • Investment thesis: CVS sits at the intersection of defensive consumer health exposure and scale advantages in pharmacy services. With a generous dividend yield and a solid balance sheet, CVS offers downside protection in volatile markets, while potential multiple expansion could arise from improving earnings power and cost discipline. Valuation is reasonable given forward earnings, but elevated leverage and competitive dynamics warrant a disciplined stance.
  • Price outlook: Moderately constructive near-term with potential upside if earnings momentum materializes. Our three-target framework implies roughly 72 (bearish), 85 (base), and 98 (bull) price scenarios, reflecting a forward-earnings-driven multiple in the ~11.8x area for 12-month horizons but with earnings volatility and leverage risk to monitor.

Fundamental Analysis

  • Current valuation and health
    • Current price: 76.74
    • Market cap: 97.33B; Enterprise value: 166.30B
    • Valuation multiples: trailing P/E ~21.38; forward P/E ~11.84; price-to-book ~1.26
    • Profitability: net margins ~1.18%; gross margins ~13.31%; operating margins ~2.80%
    • Returns: ROE ~5.88%; ROA ~2.29%
    • Leverage: debt-to-equity ~106.7%; total debt ~82.72B; total cash ~14.17B
    • Liquidity/dividend: dividend yield ~3.46%; five-year avg dividend ~3.16%
    • Volatility: beta ~0.61 (defensive name characteristics)
  • Observations
    • A relatively modest profitability profile by GAAP standards, with leverage risk given the debt load. The forward P/E of ~11.8x suggests the market is pricing in a meaningful re-acceleration in earnings versus the current troughs seen in some quarters, but this depends on CVS successfully leveraging its scale and cost synergies.

Earnings Analysis

  • Recent earnings summary (key points from the data)
    • 2025-06-30: Net Income from continuing operations ~$1.021B; Diluted EPS ~0.80; EBITDA ~$3.581B; Normalized Income ~1.021B. Indicates continued operating performance but with some dispersion versus other periods due to unusual items.
    • 2025-03-31: Net Income ~$1.779B; Diluted EPS ~1.41; EBITDA ~$4.556B; Normalized Income ~1.779B.
    • 2024-12-31 to 2024-09-30: Mixed quarters with occasional earnings softness (e.g., 2024-09-30 Diluted EPS ~0.07, a clear outlier due to unusual items) and substantial quarter-to-quarter swings in reported earnings.
  • EPS Trend (as provided)
    • 0q (most recent): current 1.3607; short-term readings around 1.36; 1-year forward indicator around 7.15; trailing numbers show a wide range depending on whether you use reported vs normalized figures.
    • 0y: 6.366; +1y: 7.153
    • Interpretation: The data imply a multi-year earnings rebound expectation from the troughs observed in some quarters, with forward-looking earnings (1y) in the mid-high single digits per share.
  • EPS Revisions (as provided)
    • 0q: no upward revisions in last 7–30 days; 4 downward revisions in the last 30 days.
    • +1q: no upward revisions in last 7 days; 3 upward revisions in last 30 days; 2 downward revisions in last 30 days.
    • 0y: 6 upward revisions in last 30 days; no downward revisions.
    • +1y: 2 upward revisions in last 7 days; 5 upward revisions in last 30 days; 1 downward revision in last 30 days.
    • Interpretation: Near-term revisions are mixed, with some downward revisions in the near term (0q), but a bias toward upward revisions over longer horizons (+1q, +1y). This suggests some analyst optimism building for the 1-year and 2-year frames, even if near-term volatility persists.

Technical Analysis (Last 60 Days)

  • 50-Day Moving Average
    • May be around the mid-60s to low-70s when observed in the data window; latest figures show MA around 71.8 on 2025-10-09 while price was 76.7, indicating the stock is trading above its 50-day moving average.
  • RSI (14)
    • Recent readings in the 60s (e.g., 60.8 on 2025-10-09), suggesting constructive momentum but not overbought.
  • MACD (12,26,9)
    • The MACD line has oscillated around the zero line, with readings near 1.5–2.0 and the signal around 1.6–1.7 at times. The most recent data show MACD around 1.5 with a slightly lower signal (1.6) on 2025-10-09, implying modest near-term momentum and potential for a bullish cross if momentum improves.

Analyst Consensus & Price Targets

  • Current analyst targets: Not provided in the data (empty {}).
  • Number of analysts: Not specified in the data.
  • Catalyst considerations: With no published consensus in the data, CVS investors should anchor expectations to forward earnings dynamics, balance-sheet risk, and the dividend trajectory rather than relying on a published consensus price target.

Price Target Analysis (Short, Mid, Long-Term)

  • Methodology note: In the absence of explicit published targets, the three price targets (Low, Median, High) are derived from a forward-earnings framework anchored by the available EPS Trend data. The forward-looking P/E used is 11.84x (forward P/E from your data). The 1-year forward EPS (from the EPS Trend +1y line) is 7.15; this yields a base-case fair value near 7.15 × 11.84 ≈ 84.6, which we round to 85 as the Median Target. The Low and High reflect downside/upside scenarios around that base case.
  • Short-Term (3 months)
    • Target: 72.00
    • Rationale: Near-term earnings volatility, ordinary-quarter noise, and the leverage risk. A low case assumes EPS near the troughs implied by recent quarterly prints and the potential for continued macro/competitive pressure in pharmacy/retail channels.
    • Key drivers: closer-to-term earnings variability, macro health-care payer mix, and cost inflation pressures.
  • Mid-Term (12 months)
    • Target: 85.00
    • Rationale: Base-case anchored to forward EPS = 7.15 and forward P/E = 11.84, giving ~84.6; rounding to 85. This level represents a fair value where CVS could realize more normalized earnings power as initiatives take effect (cost discipline, synergies, scale effects).
    • Key drivers: sustained progress on cost control, stabilization/acceleration in EBITDA, and continued dividend support improving total-return potential.
  • Long-Term (3+ years)
    • Target: 98.00
    • Rationale: Upside scenario with stronger earnings power, potential multiple expansion on earnings visibility, and continued cash generation enabling dividend growth and capital allocation efficiency.
    • Key drivers: structural improvements in operating margins, debt reduction or more favorable debt mix, and macro conditions that support a higher P/E multiple for defensives with stable cash flow.
  • Summary table
    • Target levels and implied upside to current price (76.74):
      • Low: 72.00 (−6%)
      • Median: 85.00 (+11%)
      • High: 98.00 (+28%)
    • Note: These are internally derived targets, not published broker targets. The primary driver is forward earnings leverage (1-year forward EPS from the dataset) multiplied by the stated forward P/E.

Key Risks & Opportunities

  • Key Risks
    • Leverage and debt load: Debt-to-equity ~106.7% suggests leverage risk; refinancing risk and interest costs could pressure margins.
    • Margin pressure and competition: Ongoing competition in the retail/healthcare services space; margin compression risk in pharmacy benefit management (PBM) and retail.
    • Earnings volatility: The quarterly earnings data show notable variability due to unusual items and one-off charges in some quarters; this raises near-term earnings uncertainty.
    • Regulatory environment: Healthcare policy and reimbursement dynamics can impact pricing and margins.
  • Key Opportunities
    • Dividend stability and growth potential: Current yield ~3.46% and a history of dividend payments provide total-return support, particularly in a defensive portfolio.
    • Cost discipline and scale benefits: EVP-level cost control can improve EBITDA and operating margins over time.
    • Structural tailwinds in healthcare spend: Longer-term growth in health services and PBM-related revenue streams can support earnings resilience.

Investment Recommendation

  • Recommendation: Hold
  • Rationale: CVS trades with an attractive yield and a forward-earnings-driven valuation that can justify a modest upside from the base case. However, leverage and earnings volatility introduce risk that argues for a balanced stance. The Mid-Term target around 85 suggests a reasonable upside in a normalized earnings scenario, while the Low and High targets provide a framework for risk/return in bearish/bullish scenarios.
  • Expected return (12–24 months): Base-case ~+11% to ~+15% (to ~85) depending on execution of cost controls, mix of earnings, and market multiple. Upside potential to ~98 in a strong earnings-growth scenario; downside risk toward ~72 if near-term earnings disappoint or leverage concerns materialize.

Comprehensive data references (selected highlights)

  • Price and valuation
    • Current price: 76.74
    • Forward P/E: 11.84
    • P/B: 1.26
    • Dividend yield: 3.46%
  • Earnings and margins
    • Net income (latest quarter): ~1.02B (2025-06-30)
    • Diluted EPS (latest quarter): ~0.80
    • Normalized income (latest quarters): ~1.02B (2025-06-30), ~1.78B (2025-03-31)
    • Trailing EBITDA: ~$3.58B (2025-06-30)
  • EPS trends and revisions
    • EPS Trend (1-year forward): +1y EPS ~7.15; current 0q EPS around ~1.36
    • Revisions: Mixed near-term revisions; longer-horizon revisions show some upward bias
  • Technicals (last 60 days)
    • Price above 50-day MA (latest MA ~71.8; price ~76.7)
    • RSI (14) around mid-60s; MACD near neutral to mildly bullish
  • Cash/Debt
    • Cash ~$14.17B; Debt ~$82.72B; Debt/Equity ~1.07x
    • Defensive characteristics with a meaningful yield

Appendix: Target Line Details

  • Low Target: 72.00 (blue line)
    • Time: 2025-10-10 to 2025-11-09
  • Median Target: 85.00 (orange line)
    • Time: 2025-10-10 to 2025-11-09
  • High Target: 98.00 (red line)
    • Time: 2025-10-10 to 2025-11-09

If you’d like, I can:

  • Update the targets with alternative scenarios (e.g., more bullish revenue/EBITDA growth or more conservative guidance) and plot additional lines.
  • Expand the earnings-to-price sensitivity analysis using alternative forward earnings assumptions (e.g., using different forward EPS baselines from the EPS Trend data).
Chart is loading...